Email this article Practical aspects of treatment of superficial mycoses of the skin and cutaneous appendage
- Authors: Samtsov A.V.1, Araviiskaia E.R.2, Gadzhigoroeva A.G.3, Dukhanin A.S.4, Kotrekhova L.4, Murashkin N.N.5, Tsykin A.5
-
Affiliations:
- S.M. Kirov Military Medical Academy of the Russian Ministry of Defense
- Academician I.P. Pavlov First St. Petersburg State Medical University
- Институт Красивых Волос
- Pirogov Russian National Research Medical University
- Russian National Medical Research Center for Children's Health
- Pages: 191-199
- Section: DERMATOLOGY
- Submitted: 04.12.2024
- Accepted: 13.04.2025
- Published: 24.05.2025
- URL: https://rjsvd.com/1560-9588/article/view/642561
- DOI: https://doi.org/10.17816/dv642561
- ID: 642561
Cite item
Full Text
Open Access
Access granted
Subscription or Fee Access
Abstract
in recent years, the Russian Federation has seen an increase in the incidence of superficial mycoses of the skin, a change in the nature of the disease course and spectrum of its pathogens. At the same time, the imperfection of the nosological classification and nomenclature of pathogens is noted. Besides there is a deficit of modern methods for diagnosing and treating mycoses of the skin and cutaneous appendage. These facts determine the current need to update clinical guidelines and create guidelines for onychomycosis, scalp mycoses and skin mycoses. Currently, one of the most important problems in the treatment of skin mycoses is the development of resistance to antimycotics. In this regard, it is necessary to use drugs that reduce the risk of resistance. Amorolfine, as a morpholine, acts on two different enzymes (sterol Δ14 reductase and sterol Δ7-Δ8 isomerase) and is a possible therapeutic option for overcoming antifungal resistance. It has a favorable safety profile and efficacy similar to other classes of antifungal agents. In this regard, it seems appropriate to include amorolfine in cream form in national clinical guidelines for the treatment of superficial cutaneous mycosis.
Full Text
About the authors
Alexey V. Samtsov
S.M. Kirov Military Medical Academy of the Russian Ministry of Defense
Author for correspondence.
Email: avsamtsov@mail.ru
ORCID iD: 0000-0002-9458-0872
MD, PhD, Dr. Sci. (Med.), Professor, Head of the Department of Skin and Veneral Diseases
Russian Federation, Saint PetersburgElena R. Araviiskaia
Academician I.P. Pavlov First St. Petersburg State Medical University
Email: arelenar@mail.ru
ORCID iD: 0000-0002-6378-8582
SPIN-code: 9094-9688
MD, Dr. Sci. (Med.), Professor
Russian Federation, 6/8, Lva Tolstogo street, St. Petersburg, 197089Aida Guseykhanovna Gadzhigoroeva
Институт Красивых Волос
Email: aida2010@mail.ru
ORCID iD: 0000-0003-0489-0576
Alexander S. Dukhanin
Pirogov Russian National Research Medical University
Email: das03@rambler.ru
ORCID iD: 0000-0003-2433-7727
SPIN-code: 5028-6000
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowLubov Kotrekhova
Email: zurupalubov@inbox.ru
ORCID iD: 0000-0003-2995-4249
Nikolay N. Murashkin
Russian National Medical Research Center for Children's Health
Email: dg.kuptsova@gmail.com
ORCID iD: 0000-0003-2252-8570
д.м.н., профессор, руководитель НИИ детской дерматологии, заведующий отделением дерматологии и аллергологии, врач-дерматовенеролог, главный научный сотрудник
Russian Federation, MoscowAlexey Tsykin
Email: clinderm11@gmail.com
ORCID iD: 0000-0001-5201-2984
References
Supplementary files
